What is HC Wainwright's Forecast for FENC FY2026 Earnings?

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Analysts at HC Wainwright raised their FY2026 earnings estimates for Fennec Pharmaceuticals in a research note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.66 per share for the year, up from their prior estimate of $0.63. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is ($0.11) per share.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $8.18 million. During the same period in the prior year, the business earned $0.41 EPS.

Several other research firms have also recently commented on FENC. Wedbush restated an "outperform" rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th. Craig Hallum increased their price target on shares of Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th.

Fennec Pharmaceuticals Stock Down 1.3%

NASDAQ:FENC traded down $0.10 during midday trading on Wednesday, reaching $7.87. The stock had a trading volume of 66,142 shares, compared to its average volume of 96,821. The firm has a fifty day simple moving average of $6.06 and a two-hundred day simple moving average of $6.06. Fennec Pharmaceuticals has a 12-month low of $3.96 and a 12-month high of $8.56. The stock has a market cap of $217.36 million, a P/E ratio of -78.69 and a beta of 0.32.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC acquired a new position in shares of Fennec Pharmaceuticals during the 1st quarter worth $66,000. Intech Investment Management LLC purchased a new position in Fennec Pharmaceuticals during the 4th quarter valued at about $69,000. Wells Fargo & Company MN raised its position in Fennec Pharmaceuticals by 31.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,152 shares of the company's stock worth $83,000 after acquiring an additional 3,155 shares during the last quarter. Jane Street Group LLC acquired a new position in Fennec Pharmaceuticals during the first quarter worth about $90,000. Finally, Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Fennec Pharmaceuticals in the fourth quarter valued at about $97,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Jeffrey S. Hackman purchased 13,965 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average price of $6.99 per share, for a total transaction of $97,615.35. Following the acquisition, the chief executive officer now directly owns 15,000 shares in the company, valued at approximately $104,850. The trade was a 1,349.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction on Friday, April 4th. The stock was sold at an average price of $5.25, for a total value of $52,500.00. Following the transaction, the director now directly owns 61,156 shares of the company's stock, valued at approximately $321,069. This represents a 14.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,000 shares of company stock worth $183,500. 11.76% of the stock is owned by corporate insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.